Monopar To Present Data Showcasing The Appeal Of uPAR As A Radiopharma Cancer Target And Of Its Lead Clinical Program At The 2024 SNMMI Annual Meeting

6/10/24 8:06:04 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MNPR alert in real time by email

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar's poster presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/snmmi-poster-june-2024.

Get the next $MNPR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNPR

Date	Price Target	Rating	Analyst
10/11/2024	$50.00	Buy	Rodman & Renshaw
11/1/2021	$9.00	Buy	HC Wainwright & Co.

More analyst ratings

$MNPR
Market Insights

Live Market Insights

Monopar Announces MNPR-101-RIT Abstract Accepted As A Oral Presentation At EANM'24
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled "Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors" has been accepted as a "Top-Rated Oral Presentation" within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.
6/25/24 8:12:28 AM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 15 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Monopar Therapeutics The Trade: Monopar Therapeutics Inc. (NASDAQ:MNPR) Chief Operating Officer Andrew Cittadine bought a total of 32,508 shares at an average price of $0.79. To acquire these shares, it cost around $25,574. What's Happening: On
6/24/24 7:42:29 AM ET
$MNPR
$NXL
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?
Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan
6/22/24 8:00:00 PM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care

$MNPR
Press Releases

Fastest customizable press release news feed in the world

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results and summarized recent developments. Recent Developments ALXN-1840 for Wilson disease – Late Stage On October 23, 2024, the Company entered into an exclusive license with Alexion, AstraZeneca Ra
11/8/24 8:00:00 AM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics" or the "Company"), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated
10/30/24 1:42:48 PM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics" or the "Company"), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions. Janus Henderson Investors,
10/28/24 9:15:08 PM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care

$MNPR
Leadership Updates

Live Leadership Updates

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini
7/12/21 8:00:00 AM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization
6/1/21 4:05:00 PM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Laura Kelly as Director of Clinical Operations. Ms. Kelly will be responsible for managing Monopar’s clinical programs, including the recently launched Phase 2b/3 VOICE trial for the Company’s lead drug candidate Validive®. Ms. Kelly brings a wealth of clinical research experience, including oncology and the execution of Phase 1 through Phase 4 clinical trials, to the Monopar team. Prior to
2/18/21 7:00:00 AM ET
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care

Monopar To Present Data Showcasing The Appeal Of uPAR As A Radiopharma Cancer Target And Of Its Lead Clinical Program At The 2024 SNMMI Annual Meeting

Chat with this insight

Recent Analyst Ratings for $MNPR

$MNPR Market Insights

Live Market Insights

Monopar Announces MNPR-101-RIT Abstract Accepted As A Oral Presentation At EANM'24

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

$MNPR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Monopar Therapeutics with a new price target

HC Wainwright & Co. initiated coverage on Monopar Therapeutics with a new price target

ROTH Capital initiated coverage on Monopar Therapeutics with a new price target

$MNPR Insider purchases explained

Analytical look into recent insider purchases

What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

$MNPR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$MNPR Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MNPR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

Chief Executive Officer Robinson Chandler converted options into 4,895 shares and covered exercise/tax liability with 1,918 shares, increasing direct ownership by 6% to 56,162 units (SEC Form 4)

Chief Operating Officer Cittadine Andrew converted options into 1,791 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 3% to 39,869 units (SEC Form 4)

SEC Form SC 13G filed by Monopar Therapeutics Inc.

SEC Form SC 13G filed by Monopar Therapeutics Inc.

SEC Form SC 13G filed by Monopar Therapeutics Inc.

Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

$MNPR Press Releases

Fastest customizable press release news feed in the world

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

$MNPR Leadership Updates

Live Leadership Updates

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations

$MNPR SEC Filings

Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Monopar Therapeutics Inc.

Monopar Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

Recent Analyst Ratings for
$MNPR

$MNPR
Market Insights

$MNPR
Analyst Ratings

$MNPR
Insider purchases explained

$MNPR
Insider Trading

$MNPR
Large Ownership Changes

$MNPR
Insider Purchases

$MNPR
Press Releases

$MNPR
Leadership Updates

$MNPR
SEC Filings